Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Treasury Shares (2017 - 2025)

Coherus Oncology's Treasury Shares history spans 10 years, with the latest figure at $188557.0 for Q4 2025.

  • For Q4 2025, Treasury Shares fell 75.46% year-over-year to $188557.0; the TTM value through Dec 2025 reached $188557.0, down 75.46%, while the annual FY2025 figure was $188557.0, 75.46% down from the prior year.
  • Treasury Shares for Q4 2025 was $188557.0 at Coherus Oncology, down from $768237.0 in the prior quarter.
  • Across five years, Treasury Shares topped out at $2.3 million in Q4 2022 and bottomed at $188557.0 in Q4 2025.
  • The 5-year median for Treasury Shares is $1.7 million (2023), against an average of $1.4 million.
  • The largest annual shift saw Treasury Shares surged 82.61% in 2021 before it crashed 75.46% in 2025.
  • A 5-year view of Treasury Shares shows it stood at $1.8 million in 2021, then rose by 26.55% to $2.3 million in 2022, then fell by 26.0% to $1.7 million in 2023, then tumbled by 55.51% to $768237.0 in 2024, then plummeted by 75.46% to $188557.0 in 2025.
  • Per Business Quant, the three most recent readings for CHRS's Treasury Shares are $188557.0 (Q4 2025), $768237.0 (Q4 2024), and $1.7 million (Q4 2023).